SELLAS Life Sciences Group, Inc. Insurance Settlements Receivable, Current
SELLAS Life Sciences Group, Inc. (SLS) had Insurance Settlements Receivable, Current of $474.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Notes › Nontrade Receivables
us-gaap:InsuranceSettlementsReceivableCurrent · last filed 2018-11-14
- 2018-09-30: Insurance Settlements Receivable, Current $474.00K.
- 2017-12-31: Insurance Settlements Receivable, Current $0.00.
- 2017-09-30: Insurance Settlements Receivable, Current $500.00K.
- 2016-12-31: Insurance Settlements Receivable, Current $0.00.
| Period end | Insurance Settlements Receivable, Current |
|---|---|
| 2018-09-30 | $474.00K 10-Q · filed 2018-11-14 |
| 2017-12-31 | $0.00 10-Q · filed 2018-11-14 |
| 2017-09-30 | $500.00K 10-Q · filed 2018-11-14 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 |
| 2016-03-31 | $1.70M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $21.70M 10-K · filed 2017-03-15 |
| 2014-12-31 | $0.00 10-K/A · filed 2016-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |